The exact mechanism of intracranial metastasis in renal cell carcinoma (RCC) is unknown;
however, vascular endothelial growth factor expression may contribute to formation
of cerebral lesions.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Genitourinary CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Cancer statistics, 2014.CA Cancer J Clin. 2014; 64: 9-29
- Cancer Principles and Practice of Oncology.8th ed. Lippincott Williams & Wilkins, Philadelphia, PA2008
- Distribution of metastatic sites in renal cell carcinoma: a population-based analysis.Ann Oncol. 2012; 23: 973-980
- Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival.Cancer. 2008; 113: 1641-1648
- Prognostic factors for survival in patients with brain metastases from renal cell carcinoma.Cancer. 1998; 85: 251-253
- Brain metastasis: opportunity for drug development?.Curr Opin Neurol. 2012; 25: 786-794
- Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastasis in nude mice.Clin Exp Metastasis. 2004; 21: 107-118
- Incidence of brain metastases in a cohort of patients with carcinoma of breast, colon, kidney and lung and melanoma.Cancer. 2002; 94: 2698-2705
- Pazopanib in locally advanced o metastatic renal cell carcinoma: results of a randomized phase III trial.J Clin Oncol. 2010; 28: 1061-1068
- Brain metastases.Semin Neurol. 2010; 30: 217-235
- Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.J Urol. 2015; 193: 41-47
- Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4259 patients.Int J Radiat Oncol Biolo Phys. 2010; 77: 655-661
- Renal-cell carcinoma: molecular pathways and therapies.N Engl J Med. 2007; 356: 185-187
- The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients.Cancer Res. 2005; 65: 2577-2582
- High dose cizotinib for brain metastases refractory to standard-dose crizotinib.J Thorac Oncol. 2013; 8: 85-86
- Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters.Clin Cancer Res. 2009; 15: 6062-6069
- Sunitinib in metastatic renal cell carcinoma patients with brain metastases.Cancer. 2011; 117: 501-509
- Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.Cancer. 2010; 116: 1272-1280
- Incidence of brain metastases in renal cell carcinoma treated with sorafenib.Ann Oncol. 2010; 21: 1027-1031
- Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma.Cancer. 2011; 117: 4958-4965
- High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelia growth factor receptor.Eur Urol. 2008; 53: 376-381
- What is the risk of intracranial bleeding during anti-VEGF therapy?.Neuro Oncol. 2008; 10: 624-630
- Intracerebral hemorrhage.Neurologist. 2005; 11: 311-324
- Primary intracerebral hemorrhage.J Clin Neurosci. 2006; 13: 511-517
- Safety of VEGF-targeted tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and central nervous system metastases.Proc Am Soc Clin Oncol. 2007; 25 (abstract): 246
- Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.J Clin Oncol. 2011; 29: 2557-2564
- Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma.Cancer Res. 2010; 70: 1063-1071
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomized phase 3 trial.Lancet. 2011; 378: 1931-1939
- Cyclin D3 protein content in human renal cell carcinoma in relation to cyclin D1 and clinic-pathological parameters.Acta Oncol. 2002; 41: 175-181
- Inactivation of the tumor suppressor WTX in a subset of pediatric tumors.Genes Chromosomes Cancer. 2014; 53: 67-77
- Comprehensive genomic characterization of squamous cell lung cancers.Nature. 2012; 489: 519-525
- Prolonged survival of a patient with papillary renal cell carcinoma and brain metastases using pazopanib.J Clin Oncol. 2013; 31 (17): 144
Article info
Publication history
Published online: January 21, 2016
Accepted:
January 16,
2016
Received in revised form:
December 18,
2015
Received:
September 29,
2015
Identification
Copyright
© 2016 Elsevier Inc. All rights reserved.
